Background and objectives: Paraneoplastic neuronal antibodies (PNAs) are central to diagnosing paraneoplastic neurological syndromes (PNS) yet variability in assay performance can lead to diagnostic uncertainty. Commercial indirect immunofluorescence (IIF) platforms in particular show poor sensitivity for key antibodies such as CV2/CRMP5, limiting their reliability as a first-line screening tool for PNA detection. We aimed to improve the diagnostic performance of a commercial IIF assay and assess its suitability as an initial screening method.
Kwan et al. (Sun,) studied this question.